CAMBRIDGE, Mass. (AP) — Aveo Pharmaceuticals Inc. reported a wider fourth-quarter loss Tuesday as it continued to study its experimental cancer drugs tivozanib and ficlatuzumab.

Aveo said it lost $25.2 million, or 58 cents per share, during the fourth quarter. A year earlier it posted a loss of $10.3 million, or 30 cents per share. Revenue from collaborations with companies like Astellas Pharma and Johnson & Johnson fell to $1.1 million from $12 million.

Complete your profile to continue reading and get FREE access to, part of your ALM digital membership.

Your access to unlimited content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events.
  • Access to other award-winning ALM websites including and

Already have an account?



Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join now!

  • Unlimited access to - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including and
  • Exclusive discounts on and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2022 ALM Global, LLC. All Rights Reserved.